NeuroMetrix, Inc. will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neuromodulation technology that is the first and only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company's booth #1745 for a demonstration and to review prescribing details for fibromyalgia patients.

Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6% of the U.S. adult population (5 to 15 million people). Quell Fibromyalgia emerged from the NeuroMetrix pipeline of prescription wearable neurotherapeutics, two of which received FDA Breakthrough Device Designation: fibromyalgia and chemotherapy induced peripheral neuropathy (CIPN). Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.

The device may be used during sleep. Limitations: The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109. The product labeling should be reviewed for a complete list of contraindications, precautions and warnings.